Skip to main content

Table 3 Recurrences and disease-free survival in 181 node-negative breast cancer patients after different adjuvant systemic therapies or no therapy

From: C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Subgroup

 

n

Recurrence (n [%])

DFS (P)

Chemotherapy (n = 61)

   c-myc

Amplified

19

3 (15.8)

0.1748

 

Nonamplified

42

2 (4.8)

 

HER-2/neu

Amplified

26

1 (3.8)

0.2552

 

Nonamplified

35

4 (11.4)

 

Endocrine therapy (n= 99)

   c-myc

Amplified

15

1 (6.7)

0.3325

 

Nonamplified

84

2 (2.4)

 

HER-2/neu

Amplified

22

1 (4.5)

0.6641

 

Nonamplified

77

2 (2.6)

 

No therapy (n = 21)

   c-myc

Amplified

5

1 (20.0)

0.0209*

 

Nonamplified

16

0 (0)

 

HER-2/neu

Amplified

7

0 (0)

0.4969

 

Nonamplified

14

1 (7.1)

 
  1. *P < 0.05 (log-rank test). DFS, disease-free survival.